araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker

Summary: The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.

Detailed description: Measurements of specific glycosylation changes in serum haptoglobin.

Eligibility: Arm1 (Gastric cancer patient)
  1. Inclusion Criteria:
  -  Male or female over 19 years
  -  Patients with histologically Gastric Cancer (included Gastroesphageal junction)
  -  Primary gastric cancer or/and metastatic gastric cancer.
  -  Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
  2. Exclusion Criteria:
  -  Prior or present history of malignancies other than gastric cancer
  -  Any condition that confounds the ability to interpret data from the study under the investigational confirmed.
  Arm2 (Cancer-free healthy volunteers)
  1. Inclusion Criteria:
  -  Male or female over 19 years
  -  Cancer-free status.
  -  Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
  2. Exclusion Criteria:
  -  Prior or present history of malignancies (included gastric cancer)
  -  Any condition that confounds the ability to interpret data from the study under the investigational confirmed

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks

Summary: One paraffin block is routinely used for Human Epidermal Growth Factor Receptor 2 (Her2/neu) immunohistochemistry (IHC) assessment. Here, investigators investigated if picking two or multiple paraffin blocks for Her2/neu evaluation is an economical, efficient and practical method, which may reduce false-negativity of Her2/neu IHC assessment due to intratumoral heterogeneity.


Eligibility: Inclusion Criteria:
  Age between 18 to 80; Received curative surgery with primary gastric adenocarcinoma; Did not receive any preoperative treatment.
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Summary: Objectives:
  To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat relapsed or refractory cancer.
  Eligibility:
  Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.

Detailed description: A total of 20 patients may be enrolled over a period of 1-2 years.

Eligibility: Inclusion Criteria:
  1. Age 18~65 years old, male or female;
  2. Life expectancy≥6 months;
  3. ECOG score: 0-3;
  4. Advanced solid tumor (lung cancer, gastric cancer, liver cancer) were diagnosed by pathological or clinical physicians;
  5. Enough venous channel, no other contraindications to the separation and collection of white blood cells;
  6. Immunohistochemistry and RT-PCR technology will be used to determine the positive EGFR family (including EGFR, HER2, HER4) and IGFR1 protein. At least one protein expressed in immunohistochemical tumor tissue should be no less than grade 2 or 2+ scores. The levels of protein are defined as follows: (according to cell staining) : grade 0: without staining; grade 1: 1-25%; grade 2: 26-50% and grade 3: 51-100%; (According to the intensity): negative; 1+; 2+ and 3+;
  7. Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x 10*/L, hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level；
  8. Signed informed consent；
  9. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.
  Exclusion Criteria:
  1. Expected Overall survival ＜ 6 months;
  2. Patients with uncontrolled hypertension, unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> Class II, NYHA), or myocardial infarction within 6 months.
  3. Abnormal lung function: FEV (forced expiratory volume) < 30% prediction, DLCO (diffusing capacity of the lung for carbon monoxide) < 30% prediction, blood oxygen saturation < 90%;
  4. Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;
  5. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Relevance to patient case: possibly relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Biomarker-Integrated Umbrella, Advanced Gastric Cancer

Summary: In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.


Eligibility: Inclusion Criteria:
  1. Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and gastroesophageal junction cancer
  2. Eastern Cooperative Oncology Group performance status of 0 to 1
  3. Male or female; ≥ 19 years of age
  4. On or progression after 1st line palliative chemotherapy
  5. Subjects with evaluable lesion (using RECIST 1.1 criteria)
  6. Subjects who meet the following criteria:
  -  Absolute neutrophil count ≥ 1000 /µL
  -  Platelet count ≥ 75,000/ µL
  -  Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance ≥60 mL/min
  -  aspartate aminotransferase and alanine transaminase 3 x upper limit of normal
  Exclusion Criteria:
  -  Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

Relevance to patient case: definitely relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer

Summary: The primary purpose of this study is to compare both short-term and long-term treatment effect of laparoscopic vs. open approach on progressive gastric and rectal cancer, based on circulating tumor cell (CTC) test results as well as disease-free survivals, and figure out principles of laparoscopic approach for progressive gastric and rectal cancer. Secondary purpose is to establish an evaluation system for laparoscopic surgery for progressive gastric and rectal cancer treatment using CTC as a biomarker.

Detailed description: Laparoscopic surgery represents a milestone for treatment of gastric and rectal cancer, with advantages of minimal invasion and rapid recovery compared to open approach. However, for progressive gastric and rectal cancer, laparoscopic approach has not been officially promoted by NCCN guideline (2015).
  Over the past decade, circulating tumor cells (CTCs), originated from a tumor cell, have been identified as potential blood-based biomarkers capable of providing prognostic and predictive Information.
  In the present study, the investigators utilize the CTCBIOPSY® system (YZYBIO Company, Wuhan, China), which has been approved by CFDA (Chinese Food and Drug Administration), to detect CTCs, and try to compare both short-term and long-term treatment effect of laparoscopic vs. open approach on progressive gastric and rectal cancer, based on circulating tumor cell (CTC) test results as well as disease-free survivals, and figure out principles of laparoscopic approach for progressive gastric and rectal cancer. Secondary purpose is to establish an evaluation system for laparoscopic surgery for progressive gastric and rectal cancer treatment using CTC as a biomarker.

Eligibility: Gastric cancer
  Inclusion Criteria:
  -  Gastric cancer of stage II/III
  Exclusion Criteria:
  -  History of malignant tumors
  -  Gastric cancer of stage Ⅳ
  -  Preoperative neoadjuvant chemotherapy
  -  History of upper abdominal surgery
  -  Severe other contradictions of surgery
  Rectal cancer
  Inclusion Criteria:
  -  Primary rectal carcinoma
  -  Single lesion
  -  No metastasis
  -  Sphincter-saving surgery available
  Exclusion Criteria:
  -  History of malignant tumors
  -  Acute bowel obstruction, bleeding or perforation
  -  Tumor over 6cm in diameter or in severe adhesion with surrounded tissues
  -  Severe other contradictions of surgery

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Summary: This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation


Eligibility: Inclusion Criteria:
  -  Patients with stage IIIB/IV non-small cell lung cancer
  -  Patients with uncommon epidermal growth factor receptor (EGFR) mutation
  -  Targeted-therapy-naive patients
  -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  -  Evaluable target lesions according to RECIST 1.1 for tumour response assessment
  Exclusion Criteria:
  -  Wild-type EGFR
  -  Positive 19 del and/or 21 L858R mutation
  -  Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib
  -  Patients who have documented history of interstitial lung disease

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Summary: This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).


Eligibility: Inclusion and Exclusion criteria have been removed due to Symphogen's business decision to no longer perform the clinical study.

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer

Summary: To investigate the clinical efficacy and safety of laparoscopic bursectomy and D2 lymphadenectomy (LBDL group) versus laparoscopic D2 lymphadenectomy (LDL group) in advanced gastric cancer by prospective randomized controlled clinical trial.

Detailed description: To compare the LBDL group and LDL group in the advanced gastric cancer. A prospective randomized controlled trial will be performed in the GI department, Guangdong provincial hospital of Chinese Medicine from November 2016 to November 2024. The sample size，100 cases with advanced gastric cancer, will be needed after calculated by the statistics. The 100 cases will be randomly divided into two groups: LBDL group and LDL group. Primary outcomes are the 3 years' Disease-free survival (DFS) rate, The secondary outcomes are the 3 years' and 5 years' Disease-free survival (DFS) rate, the 3 years and 5 years Overall survival（OS）rate, operative time, the total blood loss, the intra-operative complication and the post-operative complication, the number of lymph nodes dissected, the number of conversion to open laparotomy, and the other outcomes are the average time of ground activities, the hospital stay. The data in two groups will be compared.

Eligibility: Inclusion Criteria:
  1. The age limits is 18-80 years old;
  2. T3-T4 resectable gastric carcinoma,confirmed by CT and pathology.
  3. The preoperative imaging confirmed that the tumor did not involve adjacent organs;
  4. American Society of anesthesiologists (ASA) score less than or equal to Level 3;
  5. Criteria of performance status karnofsky is greater than or equal to 60.
  Exclusion Criteria:
  1. The patients' age limits is Less than 18 years old, or more than 80 years old;
  2. The preoperative imaging confirmed that the tumor involve adjacent organs;
  3. The tumor have been finding distant metastases;
  4. American Society of anesthesiologists (ASA) score more than 3;
  5. Criteria of performance status karnofsky is lower than 60;
  6. There is a laparoscopic surgery contraindications.

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Summary: The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in patients with gastric cancer and verified free cancer cells in abdominal cavity in improving the long term outcomes and overall survival of further surgical treatment.


Eligibility: Inclusion Criteria:
  -  ECOG 0-2
  -  Histologically proven gastric cancer T2-3 N+, T4a with any N (0,+) with free cancer cells in the abdominal cavity and no macroscopic canceromathosis and no other distant metastases (TNM classification 7th edition)
  -  Histological forms: gastric adenocarcinoma and signet ring cancer
  -  Blood characteristics (creatinine <150 mg/l, total bilirubin < 50 mkmol/l, neutrophils < 1500/mkl, hemoglobin >90 g/l, thrombocytes > 100000/mkl)
  Exclusion Criteria:
  -  Clinically apparent distant metastasis (besides free cancer cells)
  -  Synchronic or metachronic malignant tumors
  -  Previous systemic or surgical or combined therapy for gastric cancer
  -  Complications of gastric cancer (obstruction 0-1 GOOSS scale and/or gastric bleeding)
  -  Adhesions in abdominal cavity
  -  Gastrooesophageal junction cancer or gastric cancer with spreading on oesophagus.

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer

Summary: The results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.

Detailed description: A prospective comparison of PET/MRI and PET/CT for gastric cancer will be performed,to evaluate the value of PET/MRI in predicting the preoperative staging and resectability of gastric cancer and investigate the role of PET/MRI in gastric cancer diagnosis.The evaluation parameters are the diagnostic accuracy of gastric cancer staging( including the overall accuracy, sensitivity, and specificity) and the receiver operating characteristic (ROC).

Eligibility: Inclusion Criteria:
  1. Histological diagnosis of gastric cancer
  2. No previous treatment history for gastric cancer
  3. Without complications of obstruction,bleeding and so on
  4. Without severe diabetes,the levels of blood glucose <6.2 mmol/L .
  5. No cardiac pacemarker,never stimulator or other metal substitute materials in vivo.
  Exclusion Criteria:
  1. With other neoplastic disease.
  2. Suffering acute inflammatory disease
  3. History of chemo-radiotherapy
  4. Suffering prostate hyperplasia,glaucoma

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR TKI Therapy

Summary: A comparison of baseline tumor characteristics in EGFR mutant lung cancers to tumor characteristics after early response of EGFR-TKI targeted treatment to allow identification of early adaptive mechanisms of cell survival in the setting of oncogene-targeted therapy. This identification will facilitate targeting and termination of these survival/resistance pathways before they develop with rational combination of therapeutic agents to improve outcomes.


Eligibility: Inclusion Criteria:
  -  Carry a diagnosis of stage IV lung adenocarcinoma with an EGFR activating mutation
  -  Aged 18 - 85 years or older
  -  ECOG 0-2
  -  Have a histologically confirmed diagnosis of lung adenocarcinoma harboring an EGFR sensitizing mutation (including, but not limited to: G719X, del exon 19, or L858R).
  -  No prior therapy for metastatic disease.
  -  Planned treatment with a single agent EGFR TKI including but not limited to:
  1. erlotinib,
  2. gefitinib,
  3. rociletinib (CO-1686),
  4. afatinib, or
  5. osimertinib (AZD-9291).
  -  Patients must have at least one site of measurable disease ≥ least 2cm.
  -  Primary disease site or site of metastatic disease must be amenable to biopsy.
  -  Patients must have the ability to understand and willingness to sign an informed consent document.
  -  Patients must be willing to undergo an initial pre-treatment biopsy of tumor tissue (or have previously collected frozen tissue) and a follow-up biopsy 2 weeks (+/- 1 week) after treatment start
  Exclusion Criteria:
  -  Concurrent health problem which would preclude tissue biopsy (eg hemophilia or other bleeding predisposition).
  -  Patients whose only source of biopsiable disease is:
  1. intracranial,
  2. pleural effusion or any lesion that is deemed unsafe to biopsy by the treating physician or,
  3. interventional radiology.

Relevance to patient case: not relevant
Patient case: 60-year-old female with gastric cancer; genetic feature: EGFR

Clinical trial: The Origin of Infrapyloric Artery

Summary: Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies. This trial aims to tell the distribution of IPA origin in Chinese patients.

Detailed description: Infrapyloric artery(IPA) is of great importance for gastric cancer patients. In early gastric cancer patients, the pylorus-preserving gastrectomy requires the preserving of IPA. In advanced gastric cancer patients, the subgroup of No. 6 lymph node might be associated with IPA. In JGCA gastric cancer classification guidelines, the No. 6 lymph nodes is defined as lympn nodes along the first branch and proximal part of the right gastroepiploic artery(RGEA) down to the confluence of the right gastroepiploic vein and the anterior superior pancreatoduodenal vein. However,if IPA origins from the gastroduodenal artery(GDA) or anterior superior pancreatoduodenal artery(ASPDA), the lymph nodes along the IPA can not be grouped into the No. 6 lymph nodes. Thus, a new definition of No. 6 lymph nodes is needed on the basis of the origin of IPA.
  Previous studies about IPA origin are few and the origin of IPA varies greatly among different studies.

Eligibility: Inclusion Criteria:
  -  Patients with gastric cancer who needs to receive total or distal gastrectomy.
  -  Signed informed consent
  Exclusion Criteria:
  -  IPA not dissected, photoed or video-recorded.

Relevance to patient case: not relevant
Patient case: 78-year-old female with sarcoma; genetic feature: MDM2

Clinical trial: The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities

Summary: Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to either receive or not receive radiation therapy following surgery for the removal of the local tumor. All patients in this protocol will receive adjuvant chemotherapy.

Detailed description: Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to either receive or not receive radiation therapy following surgery for the removal of the local tumor. All patients in this protocol will receive adjuvant chemotherapy.

Eligibility: Patients must have biopsy-proven soft tissue sarcoma with one of the following diagnoses:
  Liposarcoma (round cell or pleomorphic).
  Fibrosarcoma.
  Malignant fibrous histiocytoma.
  Inflammatory malignant fibrous histiocytoma.
  Myxoid malignant fibrous histiocytoma.
  Malignant giant cell tumor.
  Angiomatoid malignant fibrous histiocytoma.
  Leiomyosarcoma.
  Malignant hemangiopericytoma.
  Rhabdomyosarcoma (embryonal, alveolar, pleomorphic or combined).
  Soft tissue sarcoma resembling Ewing's sarcoma.
  Synovial cell sarcoma.
  Epithelioid sarcoma.
  Clear cell sarcoma.
  Neurofibrosarcoma.
  Epithelioid schwannoma.
  Malignant triton tumor.
  Angiosarcoma.
  Mixed malignant mesenchymoma.
  Alvelar soft part sarcoma.
  Malignant granular cell tumor.
  All lesions must be Grade II or III. No patients with Grade I lesions will be acceptable.
  Patients must have undergone a limb-sparing procedure in which all gross tumor has been removed.
  Clinical evaluation must reveal no evidence of metastatic disease either in regional lymph nodes or more distant sites.
  The soft tissue sarcoma must be on the extremity either at or distal to the shoulder joint or at or distal to the hip joint.
  The definitive surgical procedure for a primary lesion or for a recurrence must have been performed no longer than four months from the date of randomization.
  Patients must not have received any prior chemotherapy or radiotherapy for their sarcoma.
  Patients without a history of any other malignant disease except basal cell carcinoma.
  Patients who have not had a serious infection, active bleeding disorders, or concomitant severe disease such as cirrhosis, ischemic heart disease, or evidence of severe impairment of renal function.
  Patients must be above the age of 30 and do not have a diagnosis of embryonal rhabdomyosarcoma.

Relevance to patient case: not relevant